Xenikos B Vis A Clinical Stage Biopharmaceutical Company Based In The Netherlandsfounded In 2009 By Ypke Van Oosterhoutthe Company Focuses On Developing Innovative Immunotherapiesparticularly Conjugated Antibodies Aimed At Resetting The Immune Systemtheir Mission Is To Address Severe Immune Diseases And Post Transplant Rejection Conditions Xenikos Specializes In Research And Development Of Therapies For Conditions Like Acute Graft Versus Host Diseaseagvhdand Other Severe Autoimmune Diseasestheir Flagship Productt Guardis Designed To Reset The Immune System And Has Shown Potential In Treating Transplant Related Rejection And Severe Autoimmune Diseasesalthough The Phase 3 Clinical Trial For T Guard Was Discontinued In Early 2023The Company Remains Committed To Contributing To Future Research In This Field
No conferences found for this company.
| Company Name | Xenikos Bv |
| Country |
Netherlands
|
| Address | N/A |
| Telephone | N/A |
| N/A |
